1. SSKN presented at TeraCILAD 2025, showcasing key dermatologic technologies. 2. Expect 12 new TheraclearX® accounts in Mexico by year-end 2025. 3. Dermatologists are adopting device-based treatments for acne and skin disorders. 4. XTRAC® and TheraclearX® exhibit promise in expanding market presence. 5. Strong interest in non-pharmaceutical solutions highlights SSKN's growth potential.
FAQ
Why Bullish?
Growing adoption of TheraclearX® can lead to increased revenues, mirroring past successes with XTRAC®.
How important is it?
The article details strategic growth and market expansion, indicating a strong potential impact on SSKN’s stock performance.
Why Long Term?
The establishment of over 12 recurring accounts suggests sustainable revenue, indicating long-term value creation for investors.
STRATA Skin Sciences Showcases Innovative Dermatology Solutions at TeraCILAD 2025
HORSHAM, Pa. — December 9, 2025 — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a pioneer in in-office dermatologic technologies, made significant strides at the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD), held from November 19-22, 2025. The company presented its advanced XTRAC® excimer laser and the TheraclearX® acne therapy system, reporting that over 12 new recurring TheraclearX® accounts are expected in Mexico by the end of 2025, showcasing a growing acceptance amongst dermatologists in the region.
Key Highlights from TeraCILAD 2025
- STRATA presented XTRAC®, a leading targeted UVB excimer laser effective for treating psoriasis, vitiligo, and other skin conditions.
- TheraclearX®, now available in Mexico, offers a non-drug, device-based solution for acne treatment.
- By year-end 2025, the company anticipates over a dozen recurring accounts for TheraclearX® in Mexico.
- The conference provided a platform for engaging with Ibero-Latin American dermatology leaders and discussing clinical outcomes.
Insights from Clinical Presentations
Dr. Melissa Lomeli, the first user of TheraclearX® in Mexico, captivated the audience with her presentation titled, “ThéraClearX: Rewriting the Protocol for the Treatment of Mild to Moderate Acne.” She emphasized the remarkable potential of the technology, stating, “What would happen if I told you that acne can improve in just one 20-minute session? It sounds too good to be true, right? Today, I’m going to show you why it is possible.”
During the conference, Dr. Henry Lim, a prominent figure in dermatology and President of the International League of Dermatological Societies, delivered a talk on the efficacy of XTRAC® for various skin conditions, reinforcing its recognized effectiveness in treating inflammatory disorders.
Market Context and Adoption Trends
As one of the top dermatology congresses in the Ibero-Latin American region, TeraCILAD 2025 allowed STRATA to demonstrate the clinical effectiveness of its technologies. The XTRAC® excimer laser is celebrated for its precision, while TheraclearX® is increasingly recognized as an innovative, non-pharmaceutical acne treatment.
Shmuel Gov, STRATA's Chief Operating Officer, commented, “We were very encouraged by the level of interest and engagement we saw at TeraCILAD, around both XTRAC and TheraclearX. Dermatologists are clearly seeking effective, non-systemic treatment options to integrate into routine clinical practice.”
The early commercial placements of TheraclearX® in Mexico reflect growing dermatologist confidence in its efficacy, contributing to STRATA’s objective of establishing sustainable revenue streams in the region.
Strategic Outlook and Future Prospects
STRATA continues to focus on expanding access to advanced dermatological solutions globally. The company’s participation at TeraCILAD 2025 reinforces its commitment to engage with key opinion leaders and support dermatologists with innovative treatments while increasing revenue opportunities through device-based therapies.
CEO Dolev Rafaeli added, “While it is still early to estimate the commercial value of each placement, previous XTRAC placements indicate that we can generate upwards of $30,000 in annual revenue per clinic.”
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a dedicated medical technology company promoting innovative products for the treatment of dermatological conditions, including psoriasis, vitiligo, and acne. Its product offerings include the XTRAC® excimer laser and the TheraclearX® Acne Therapy System.
STRATA's partnership approach, which entails a fee per treatment rather than outright purchase, supports practices through equipment installation, training, and ongoing service, ensuring maximum efficiency and effectiveness in patient care.
Safe Harbor Statement
This release contains forward-looking statements as defined by the Securities Litigation Reform Act of 1995. These statements include future plans and expectations regarding operational performance. Variances may arise due to economic, regulatory, and market factors. Investors are encouraged to review STRATA’s SEC filings for a comprehensive understanding of risks and uncertainties.